Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for treating small-cell lung cancer after platinum-based chemotherapy [1126] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1126 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for treating small-cell lung cancer after platinum-based chemotherapy [1126] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for treating small-cell lung cancer after platinum-based chemotherapy. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 16 September 2019 | Suspended. Referred 05/12/2016 |
| 29 November 2018 | As you are aware the Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for treating small-cell lung cancer after platinum-based chemotherapy. However, the company have advised that the Phase III CheckMate -331 Study did not meet its primary endpoint of Overall Survival with Opdivo versus Chemotherapy in patients with previously treated relapsed small cell lung cancer. Therefore, the timelines for this appraisal are to be confirmed whilst NICE continues to liaise with company on the next steps. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes |
| 24 September 2018 - 22 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual